Mr. Bloom's practice is focused on the representation of emerging and public life science companies, and he serves as principal outside or general counsel to leading life science companies. In addition to day-to-day corporate counseling and strategic advice to his clients, he regularly handles a variety of major business transactions, including public offerings, mergers and acquisitions, venture capital financings and strategic commercial transactions.
Mr. Bloom’s representative clients include, among others: 5AM Ventures; Akero Therapeutics; Alkermes; Alnylam Pharmaceuticals; Aptinyx; Assembly Biosciences; Atlas Venture; BeiGene; Black Diamond Therapeutics; BridgeBio; Cabaletta; Century Therapeutics; Cullinan Oncology; ElevateBio; Esperion Therapeutics; Fusion Pharmaceuticals; Gemini Therapeutics; Global Blood Therapeutics; iTeos Therapeutics; Karuna Therapeutics; MPM Capital; MyoKardia; Neon Therapeutics; Nimbus Therapeutics; ProQR Therapeutics; PureTech Health; Relay Therapeutics; resTORbio; Rheos Medicines; Sage Therapeutics; Tango Therapeutics; TCR2 Therapeutics; Third Rock Ventures; Vericel Corporation; Versant Ventures and Zafgen.
Mr. Bloom is a member of the American, Massachusetts and Boston Bar Associations.
Prior to joining Goodwin, Mr. Bloom was a partner at Testa, Hurwitz & Thibeault in Boston, where he was a member of the Business Practice Group and co-chair of its Life Sciences Practice.